China Pharma Holdings Stock Last Dividend Paid

Understanding the fundamental principles of building solid financial models for China Pharma is extremely important. It helps to project a fair market value of China Stock properly, considering its historical fundamentals such as Last Dividend Paid. Since China Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of China Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of China Pharma's interrelated accounts and indicators.

Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.

Based on the recorded statements, China Pharma Holdings has a Last Dividend Paid of 0.0. This indicator is about the same for the Pharmaceuticals average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

We derive many important indicators used in calculating different scores of China Pharma from analyzing China Pharma's financial statements. These drivers represent accounts that assess China Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of China Pharma's important valuation drivers and their relationship over time.

The Macroaxis Fundamental Analysis modules help investors analyze China Pharma Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of China Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of China Pharma Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Check out China Pharma Piotroski F Score and China Pharma Altman Z Score analysis. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between China Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.